Heinrich Kovar

List of Publications by Year in Descending Order

55 papers	5,562 citations	32 h-index	61 g-index
61 ext. papers	6,501 ext. citations	10.8 avg, IF	5.26 L-index

#	Paper	IF	Citations
55	Mechanisms, Diagnosis and Treatment of Bone Metastases. *Cells*, **2021**, 10,	7.9	7
54	Ewing Sarcoma-Diagnosis, Treatment, Clinical Challenges and Future Perspectives. *Journal of Clinical Medicine*, **2021**, 10,	5.1	23
53	YAP/TAZ inhibition reduces metastatic potential of Ewing sarcoma cells. *Oncogenesis*, **2021**, 10, 2	6.6	15
52	The YAP/TAZ Pathway in Osteogenesis and Bone Sarcoma Pathogenesis. *Cells*, **2020**, 9,	7.9	28
51	Low-frequency variation near common germline susceptibility loci are associated with risk of Ewing sarcoma. *PLoS ONE*, **2020**, 15, e0237792	3.7	2
50	ETS Proteins Bind with Glucocorticoid Receptors: Relevance for Treatment of Ewing Sarcoma. *Cell Reports*, **2019**, 29, 104-117.e4	10.6	7
49	EWS-FLI1 modulated alternative splicing of ARID1A reveals novel oncogenic function through the BAF complex. *Nucleic Acids Research*, **2019**, 47, 9619-9636	20.1	23
48	Selective enhancer changes in osteosarcoma lung metastasis. *Nature Medicine*, **2018**, 24, 126-127	50.5	7
47	Genome-wide association study identifies multiple new loci associated with Ewing sarcoma susceptibility. *Nature Communications*, **2018**, 9, 3184	17.4	25
46	Identifying the druggable interactome of EWS-FLI1 reveals MCL-1 dependent differential sensitivities of Ewing sarcoma cells to apoptosis inducers. *Oncotarget*, **2018**, 9, 31018-31031	3.3	3
45	Ewing sarcoma. *Nature Reviews Disease Primers*, **2018**, 4, 5	51.1	255
44	DNA methylation heterogeneity defines a disease spectrum in Ewing sarcoma. *Nature Medicine*, **2017**, 23, 386-395	50.5	128
43	High-throughput RNAi screen in Ewing sarcoma cells identifies leucine rich repeats and WD repeat domain containing 1 (LRWD1) as a regulator of EWS-FLI1 driven cell viability. *Gene*, **2017**, 596, 137-146	3.8	11
42	Combinatorial Drug Screening Identifies Ewing Sarcoma-specific Sensitivities. *Molecular Cancer Therapeutics*, **2017**, 16, 88-101	6.1	13
41	Synthetic lethality between the cohesin subunits and in diverse cancer contexts. *ELife*, **2017**, 6,	8.9	50
40	The role of miR-17-92 in the miRegulatory landscape of Ewing sarcoma. *Oncotarget*, **2017**, 8, 10980-10993	3.3	12
39	C/EBP□1 promotes transformation and chemoresistance in Ewing sarcoma cells. *Oncotarget*, **2017**, 8, 26013-26026	3.3	11

38	EWS-FLI1 confers exquisite sensitivity to NAMPT inhibition in Ewing sarcoma cells. *Oncotarget*, **2017**, 8, 24679-24693	3.3	18
37	Combined experience of six independent laboratories attempting to create an Ewing sarcoma mouse model. *Oncotarget*, **2017**, 8, 34141-34163	3.3	52
36	Increased survival and cell cycle progression pathways are required for EWS/FLI1-induced malignant transformation. *Cell Death and Disease*, **2016**, 7, e2419	9.8	16
35	The second European interdisciplinary Ewing sarcoma research summit--A joint effort to deconstructing the multiple layers of a complex disease. *Oncotarget*, **2016**, 7, 8613-24	3.3	38
34	EWS-FLI1 impairs aryl hydrocarbon receptor activation by blocking tryptophan breakdown via the kynurenine pathway. *FEBS Letters*, **2016**, 590, 2063-75	3.8	9
33	Epigenome mapping reveals distinct modes of gene regulation and widespread enhancer reprogramming by the oncogenic fusion protein EWS-FLI1. *Cell Reports*, **2015**, 10, 1082-95	10.6	129
32	Ewing Sarcoma: Current Management and Future Approaches Through Collaboration. *Journal of Clinical Oncology*, **2015**, 33, 3036-46	2.2	356
31	EWS-FLI1 employs an E2F switch to drive target gene expression. *Nucleic Acids Research*, **2015**, 43, 2780-9	10.1	32
30	SLFN11: AchillesTHeel or Troublemaker. *Clinical Cancer Research*, **2015**, 21, 4033-4	12.9	
29	YK-4-279 effectively antagonizes EWS-FLI1 induced leukemia in a transgenic mouse model. *Oncotarget*, **2015**, 6, 37678-94	3.3	21
28	Blocking the road, stopping the engine or killing the driver? Advances in targeting EWS/FLI-1 fusion in Ewing sarcoma as novel therapy. *Expert Opinion on Therapeutic Targets*, **2014**, 18, 1315-28	6.4	40
27	Overexpression of HOX genes is prevalent in Ewing sarcoma and is associated with altered epigenetic regulation of developmental transcription programs. *Epigenetics*, **2014**, 9, 1613-25	5.7	36
26	Suppression of deacetylase SIRT1 mediates tumor-suppressive NOTCH response and offers a novel treatment option in metastatic Ewing sarcoma. *Cancer Research*, **2014**, 74, 6578-88	10.1	50
25	Oncogenic ETS fusions deregulate E2F3 target genes in Ewing sarcoma and prostate cancer. *Genome Research*, **2013**, 23, 1797-809	9.7	75
24	Notch is active in Langerhans cell histiocytosis and confers pathognomonic features on dendritic cells. *Blood*, **2012**, 120, 5199-208	2.2	59
23	Lysine-specific demethylase 1 (LSD1/KDM1A/AOF2/BHC110) is expressed and is an epigenetic drug target in chondrosarcoma, Ewing's sarcoma, osteosarcoma, and rhabdomyosarcoma. *Human Pathology*, **2012**, 43, 1300-7	3.7	98
22	Common variants near TARDBP and EGR2 are associated with susceptibility to Ewing sarcoma. *Nature Genetics*, **2012**, 44, 323-7	36.3	124
21	Dr. Jekyll and Mr. Hyde: The Two Faces of the FUS/EWS/TAF15 Protein Family. *Sarcoma*, **2011**, 2011, 837474	3.1	81

20	Notch signalling is off and is uncoupled from HES1 expression in Ewing's sarcoma. *Journal of Pathology*, **2011**, 225, 353-63	9.4	27
19	Hypoxia modulates EWS-FLI1 transcriptional signature and enhances the malignant properties of Ewing's sarcoma cells in vitro. *Cancer Research*, **2010**, 70, 4015-23	10.1	54
18	Intercohort gene expression co-analysis reveals chemokine receptors as prognostic indicators in Ewing's sarcoma. *Clinical Cancer Research*, **2010**, 16, 3769-78	12.9	52
17	Downstream EWS/FLI1 - upstream Ewing's sarcoma. *Genome Medicine*, **2010**, 2, 8	14.4	48
16	AURKA inhibitors: right in time. *Pediatric Blood and Cancer*, **2010**, 55, 3-4	3	2
15	EZH2 is a mediator of EWS/FLI1 driven tumor growth and metastasis blocking endothelial and neuro-ectodermal differentiation. *Proceedings of the National Academy of Sciences of the United States of America*, **2009**, 106, 5324-9	11.5	228
14	A molecular function map of Ewing's sarcoma. *PLoS ONE*, **2009**, 4, e5415	3.7	135
13	EWS-FLI1 suppresses NOTCH-activated p53 in Ewing's sarcoma. *Cancer Research*, **2008**, 68, 7100-9	10.1	85
12	Caveolin-1 (CAV1) is a target of EWS/FLI-1 and a key determinant of the oncogenic phenotype and tumorigenicity of Ewing's sarcoma cells. *Cancer Research*, **2006**, 66, 9937-47	10.1	117
11	Ewing's sarcoma family of tumors: current management. *Oncologist*, **2006**, 11, 503-19	5.7	361
10	EWS-FLI1 target genes recovered from Ewing's sarcoma chromatin. *Oncogene*, **2005**, 24, 2512-24	9.2	69
9	Context matters: the hen or egg problem in Ewing's sarcoma. *Seminars in Cancer Biology*, **2005**, 15, 189-96	12.7	71
8	Interaction of the EWS NH2 terminus with BARD1 links the Ewing's sarcoma gene to a common tumor suppressor pathway. *Cancer Research*, **2002**, 62, 4583-7	10.1	38
7	The Ewing family of tumors and the search for the Achilles heel. *Current Opinion in Oncology*, **1999**, 11, 275-84	4.2	47
6	Ewing's sarcoma and peripheral primitive neuroectodermal tumors after their genetic union. *Current Opinion in Oncology*, **1998**, 10, 334-42	4.2	76
5	Among genes involved in the RB dependent cell cycle regulatory cascade, the p16 tumor suppressor gene is frequently lost in the Ewing family of tumors. *Oncogene*, **1997**, 15, 2225-32	9.2	126
4	NPM/ALK gene fusion transcripts identify a distinct subgroup of null type Ki-1 positive anaplastic large cell lymphomas. *British Journal of Haematology*, **1996**, 92, 866-71	4.5	15
3	Detection of tumour cells in peripheral blood and bone marrow from Ewing tumour patients by RT-PCR. *International Journal of Cancer*, **1995**, 64, 135-9	7.5	72

2	Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. *Nature*, **1992**, 359, 162-5	50.4	1517
1	MIC2 is a specific marker for Ewing's sarcoma and peripheral primitive neuroectodermal tumors. Evidence for a common histogenesis of Ewing's sarcoma and peripheral primitive neuroectodermal tumors from MIC2 expression and specific chromosome aberration. *Cancer*, **1991**, 67, 1886-93	6.4	568